Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
Centre de Recherche en biomédecine de Strasbourg INSERM UMR-S1118
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient \> 18 years old
Diagnosed with localized breast cancer
Indication for first-line surgery or anthracycline-based chemotherapy.
You may not be if
History of chemotherapy or targeted therapy or immunotherapy administered before inclusion
Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2
Patient with known heart disease (ischemic, rhythmic, valvular, etc.)
Patient with a Glomerular filtration rate \< 45 mL/min/1.73m² according to the pre-therapeutic assessment
Patient with impaired liver function
Patient who is pregnant or breastfeeding
Patient with a second cancer undergoing treatment
Patient under guardianship or curatorship, protection of justice or deprived of liberty
Clareo Health | Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
